Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06852976 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
A Phase 2 study of Diabetic Foot Ulcer, sponsored by Zhuhai Rui-Inno Pharmaceutical Technology Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06852976: Recruiting Phase 2 study of Diabetic Foot Ulcer, sponsored by Zhuhai Rui-Inno Pharmaceutical Technology Co..
NCT06852976 is a Phase 2 study of Diabetic Foot Ulcer that is actively recruiting participants, run by Zhuhai Rui-Inno Pharmaceutical Technology Co.. The registered enrollment target is 60 participants, below the 254-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06852976, a Phase 2 study of Diabetic Foot Ulcer, is actively recruiting participants, sponsored by Zhuhai Rui-Inno Pharmaceutical Technology Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50% after 12 weeks of treatment.
Primary Outcome
Incidence (severity and causality) of any drug related local and systemic treatment emergent adverse events （TEAE） for 12 weeks during the study treatment.
Conditions Studied
Interventions
- DRUG 0.75% MDI-1228_mesylate gel plus Standard of Care
- OTHER Standard of Care Alone
Study Locations (1)
North Carolina
- Site 001 - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT06852976 shows while recruiting
NCT06852976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 254-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which 0.75% MDI-1228_mesylate gel plus Standard of Care is the first listed.
NCT06852976 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06852976 about?
NCT06852976 is a clinical study titled "A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers". The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50...
What is the current status of trial NCT06852976?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03-12. Estimated completion is 2025-12.
What conditions does trial NCT06852976 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer.
What interventions are being tested in trial NCT06852976?
The interventions under investigation include: 0.75% MDI-1228_mesylate gel plus Standard of Care (DRUG), Standard of Care Alone (OTHER).
Who is sponsoring clinical trial NCT06852976?
This trial is sponsored by Zhuhai Rui-Inno Pharmaceutical Technology Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06852976 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06852976's enrollment target sits among peer trials
60 44th of 67 higher than 21 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Smart Boot Use to Measure Offloading Adherence
RECRUITING · Phase 2
-
Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers
COMPLETED · Phase 2
-
Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers
COMPLETED · Phase 2
-
Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)
COMPLETED · Phase 2
-
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI